Ligand signs license agreement with Roivant Sciences
Ligand Pharmaceuticals signed a license agreement extending Roivant sciences exclusive global rights to develop and commercialize LGD-6972, ligand's glucagon receptor antagonist.
As…
Read More...
Read More...
